Related Experiment Video

Updated: Aug 9, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

Anti-ischaemic effect of ivabradine

Roberto Ferrari1, Anna Cargnoni, Claudio Ceconi

  • 1University of Ferrara, Italy. fri@dns.unife.it

Pharmacological Research
|April 29, 2006
PubMed

Insights

Ivabradine selectively inhibits the If current to reduce heart rate without negative inotropic effects. This heart rate reduction improves myocardial energetics and perfusion in patients with chronic ischemic heart disease.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ivabradine is a novel heart rate-reducing agent.
  • It selectively inhibits the If current in the sinoatrial node.

Purpose of the Study:

  • To investigate the effects of ivabradine on heart rate and myocardial function.
  • To explore the clinical benefits of ivabradine in patients with chronic ischemic heart disease.

Main Methods:

  • Selective inhibition of the If current.
  • Electrophysiological studies to assess diastolic depolarization.
  • Evaluation of myocardial perfusion and contractility during exercise and ischemia.
  • Assessment of left ventricular function in heart failure and post-myocardial infarction.

Main Results:

  • Ivabradine reduces heart rate by decreasing the slope of diastolic depolarization.
  • It preserves coronary vasodilatation and myocardial perfusion during exercise.
  • No negative inotropic effects or reduction in cardiac contractility were observed.
  • Ivabradine demonstrated protective effects during myocardial ischemia, improved left ventricular function in heart failure, and reduced remodeling post-myocardial infarction.

Conclusions:

  • Selective If current inhibition with ivabradine offers a pure heart rate reduction.
  • This mechanism decreases myocardial oxygen demand, improves energetics, and enhances perfusion in ischemic myocardium.
  • Distinct clinical benefits are anticipated from long-term heart rate reduction using ivabradine in chronic ischemic heart disease patients.

More Related Videos

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures10:01

Improvement of a Closed Chest Porcine Myocardial Infarction Model by Standardization of Tissue and Blood Sampling Procedures

Published on: March 12, 2018

The Intra-Aortic Balloon Pump06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

Related Concept Videos

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...